TimothyJEberleinMD
General Surgery • Saint Louis, MOBreast, Surgical Oncology (Other than Breast)
Director, Siteman Cancer Center and Senior Associate Dean for Cancer Programs at Washington University School of Medicine
Dr. Eberlein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-362-8020Fax+1 314-747-4871
Summary
- Dr. Timothy Eberlein is a general surgeon in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital, Barnes-Jewish West County Hospital, St. Louis Children's Hospital, and Siteman Cancer Center. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 40 years. He is Director of Siteman Cancer Center and Senior Associate Dean for Cancer Programs at Washington University School of Medicine. He has more than 180 publications and well over 500 citings.
Education & Training
Brigham and Women's HospitalResidency, Surgery, 1982 - 1985- Brigham and Women's HospitalResidency, Surgery, 1977 - 1979
University of Pittsburgh School of MedicineClass of 1977
Certifications & Licensure
MO State Medical License 1998 - 2025
MA State Medical License 1978 - 2001
MD State Medical License 1980 - 1988- American Board of Surgery Surgery
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Join now to see all
Clinical Trials
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
- LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
- Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
- Join now to see all
Publications & Presentations
PubMed
- 331 citationsDisruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic CancerMarcus C.B. Tan, Peter S. Goedegebuure, Brian A. Belt, Brian Flaherty, Narendra V. Sankpal
Journal of Immunology. 2009-02-01 - 1131 citationsPrevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast AdenocarcinomaUdaya K. Liyanage, Todd T. Moore, Hong-Gu Joo, Yoshiyuki Tanaka, Virginia Herrmann
Journal of Immunology. 2002-09-01 - 225 citationsEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialRebecca Aft, Michael Naughton, Kathryn Trinkaus, Mark A. Watson, Lourdes R. Ylagan
The Lancet. Oncology. 2010-05-01
Authored Content
- Interim Analysis of a Prospective, Multi-Institutional Study of Surgery Resident Experience with Flexibility in Surgical TrainingJanuary 2018
Press Mentions
Siteman Cancer Center to Take Patients Sept. 30September 15th, 2024- Siteman to Welcome First Patients in New Building Dedicated Exclusively to Cancer CareSeptember 10th, 2024
- St. Louis Medical Experts Are Making Advances in Cancer CareAugust 14th, 2024
- Join now to see all
Grant Support
- Program LeadersNational Cancer Institute2010–2011
- Planning And EvaluationNational Cancer Institute2010–2011
- Cancer Center AdministrationNational Cancer Institute2010–2011
- Senior LeadershipNational Cancer Institute2004–2011
- Protocol Specific Research SupportNational Cancer Institute2004–2011
- Developmental FundsNational Cancer Institute2004–2011
- Cancer Center Support GrantNational Cancer Institute2001–2011
- Surgical Oncology Training GrantNational Cancer Institute1999–2011
- Core--Bioinformatics FacilityNational Cancer Institute2004–2008
- Staff InvestigatorsNational Cancer Institute2004
- Program Planning And EvaluationNational Cancer Institute2004
- T Cell Immune Response To Breast CarcinomaNational Cancer Institute1998–1999
- Cancer Center Planning GrantNational Cancer Institute1997–1998
- T-Cell Immune Response To Breast CarcinomaNational Cancer Institute1995–1998
- Advanced Training In Surgical OncologyNational Cancer Institute1988–1998
- Immune Response To Ovarian CarcinomaNational Cancer Institute1994–1997
- Alternative Method Of Adoptive ImmunotherapyNational Cancer Institute1989–1994
- An Alternative Method Of Adoptive ImmunotherapyNational Cancer Institute1993
- Adoptive Immunotherapy In The Mouse And HumanNational Cancer Institute1985–1987
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
